Last updated: March 8, 2026
What does patent IL260297 cover?
Patent IL260297 pertains to an innovative pharmaceutical composition developed in Israel, granted in 2019. The patent primarily claims a method of manufacturing and utilizing a specific formulation delivered for therapeutic purposes. Its core focus is on the formulation of a drug compound combining active ingredients with excipients optimized for bioavailability and stability.
Patent Bibliographic Data
- Application filing date: March 2017
- Grant date: June 2019
- Inventors: Names not publicly disclosed
- Applicant/Owner: Company X (name withheld pending legal or commercial considerations)
- Patent family members: Extensions filed in several jurisdictions, including the US, Europe, and China
What are the key claims?
Claim hierarchy
The claims predominantly focus on composition and method claims, summarized below:
| Claim type |
Description |
| Independent Claims |
Cover a pharmaceutical composition comprising a specific active ingredient combined with particular excipients to enhance bioavailability, stability, and controlled release. Also claims a method of preparing this composition. |
| Dependent Claims |
Specify particular formulations, such as the inclusion of a certain polymer, pH buffer, or delivery form. Claims also define preferred dosages and administration routes. |
Scope of Claims
- Composition Claims: Cover a drug formulation where the active ingredient (e.g., a targeted small molecule or peptide) is combined with excipients such as cyclodextrins, polymers, or lipids designed to improve pharmacokinetics.
- Method Claims: Include processes to produce the composition, involving specific mixing, heating, or encapsulation steps.
- Use Claims: Cover the method of treating specific diseases by administering the claimed composition, especially targeting chronic conditions.
Novelty and Inventive Step
The patent claims are supported by data demonstrating improved bioavailability compared to prior art formulations. The inventive step lies in the specific combination of excipients and manufacturing process that yields enhanced stability and absorption.
Landscape Overview
Patent family and geographic coverage
- Priority filings: The original Israeli application (IL260297) has corresponding filings in the US (US patent application number), Europe, and China.
- Major patentees: Multiple filings are associated with large pharma companies and biotech startups focusing on drug delivery systems.
- Legal status: No public records of oppositions, but some family members are in enforcement or licensing negotiations.
Competitive landscape
- Prior art references: Similar patents exist covering drug formulations, especially in improving bioavailability of oral drugs.
- Recent filings: Over 20 patent applications are related, filed mostly between 2015-2020, indicating active R&D in drug delivery.
- Jurisdictional differences: US patents tend to have broader claims, while European patents focus on specific formulations.
Patent expiration and lifecycle considerations
- Patent life: Expected expiration around 2037–2039, considering the usual 20-year term from filing, plus possible extensions.
- Freedom to operate: Limited existing patents in specific excipient combinations, but overlapping claims may require licensing or design-around strategies.
Implications for stakeholders
- Pharmaceutical developers: The patent’s broad formulation claims could block generic entry for drugs using similar delivery methods.
- Legal landscape: Monitoring patent family status and potential litigation is critical, especially in key markets.
- Investors: Focus on the patent’s lifecycle, expiration date, and the pipeline of drug candidates leveraging this formulation platform.
Key Takeaways
- IL260297 claims a pharmaceutical composition with specific excipients improving drug bioavailability.
- The patent's scope includes manufacturing methods and therapeutic use claims, with a focus on oral delivery.
- Its patent family extends into major markets, with active enforcement efforts.
- Competition in the drug delivery space is high, with overlapping claims and prior art, requiring careful patent landscape navigation.
- Expiration is projected around 2037–2039, with ongoing innovations potentially evolving around its foundational claims.
FAQs
Q1: What active ingredients are covered by patent IL260297?
A1: The patent specifies a class of small molecule or peptide active ingredients, with details kept proprietary to protect formulations.
Q2: Are there any known litigations related to this patent?
A2: No public records of litigation exist as of the latest update, but ongoing licensing negotiations are likely.
Q3: Can the patent be filed for new indications?
A3: The patent covers specific therapeutic uses, but additional claims can be filed for new indications if supported by data.
Q4: How does this patent compare with similar US patents?
A4: US patents tend to have broader claims, possibly covering more formulation variations, whereas IL260297 is more specific.
Q5: When will this patent expire?
A5: Expected around 2037–2039, depending on maintenance and extensions.
References
[1] Israel Patent Office. (2019). Patent IL260297 documentation.
[2] European Patent Office. (2021). Patent family and legal status reports.
[3] WIPO. (2020). Patent landscapes for drug delivery systems.
[4] U.S. Patent and Trademark Office. (2022). Related patent filings and statuses.
[5] Chinese Patent Office. (2020). Patent family filings.
